Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 13/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 12/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.54 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.52 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.52 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4963629 | 0.84 | KMT2A (0.48) | OPRM1OPRD1OPRK1GRIN2DGRIN3B | |
| SCHEMBL4964063 | 0.83 | OPRM1 (0.53) | OPRM1OPRD1OPRK1GRIN2DGRIN3B | |
| SCHEMBL3700420 | 0.81 | OPRM1 (0.79) | OPRM1OPRD1OPRK1GRIN2DGRIN3B | |
| SCHEMBL4965841 | 0.80 | OPRM1 (0.41) | OPRM1OPRD1OPRK1GRIN2DGRIN3B | |
| SCHEMBL4964019 | 0.80 | SLC8A1 (0.50) | OPRM1OPRD1OPRK1GRIN2DGRIN3B | |
| SCHEMBL4963654 | 0.79 | SLC8A1 (0.44) | OPRM1OPRD1OPRK1GRIN2DGRIN3B | |
| SCHEMBL3697152 | 0.78 | OPRM1 (0.82) | OPRM1OPRD1OPRK1GRIN2DGRIN3B | |
| SCHEMBL3702966 | 0.77 | OPRM1 (0.70) | OPRM1OPRD1OPRK1GRIN2DGRIN3B | |
| SCHEMBL4965435 | 0.75 | PARP15 (0.50) | OPRM1OPRD1OPRK1PARP10 | |
| SCHEMBL3695244 | 0.73 | OPRM1 (0.81) | OPRM1OPRD1OPRK1GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606275-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-08-27 | — | — | EP | claimed |
| US-20060166987-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY | 2006-07-27 | — | — | US | claimed |
| EP-1606275-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-12-21 | — | — | EP | claimed |
| WO-2004080996-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-09-23 | — | — | WO | claimed |
| EP-1606275-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-08-27 | — | — | EP | disclosed |
| US-7396943-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-07-08 | — | — | US | disclosed |
| US-20060166987-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY | 2006-07-27 | — | — | US | disclosed |
| EP-1606275-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004080996-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166987-A1 | Opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | OPRM1 1/4885OPRD1 2/4885OPRK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.